Roivant, Priovant Say Dermatomyositis Treatment Meets Main Goal in Phase 3 Study; Shares up Pre-Bell
MT Newswires Live
Sep 17
Roivant Sciences (ROIV) and Priovant Therapeutics said Wednesday that a phase 3 study of brepocitinib to treat dermatomyositis showed a "clinically meaningful and statistically significant improvement," compared with placebo on the primary endpoint and all nine key secondary endpoints.
The observed safety profile of a 30-milligram dose was consistent with previous brepocitinib clinical trials, the companies said. Priovant intends to file a new drug application for brepocitinib in dermatomyositis in H1 2026.
Dermatomyositis is a multi-organ idiopathic inflammatory condition that is characterized by debilitating muscle weakness and skin lesions.
Roivant shares were up 9.2% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.